Related Experiment Video
Updated: Jul 3, 2025

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
Published on: June 13, 2018
Lnc-CLSTN2-1:1 Promotes Osteosarcoma Progression by Disrupting Redox Balance through PI3K/AKT Signaling Pathway
Hao Lin1, Xinjian Wei1, Junhong Ye1
1Department of Orthopedics, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong,534001, China.
Abstract:
Objective: Most patients with osteosarcoma (OS) have an extremely poor prognosis. The primary purpose of this investigation was to explore the biological effect of Lnc-CLSTN2-1:1 on OS and the potential processes involved. Materials and procedures: We selected differentially overexpressed Lnc-CLSTN2-1:1 from our laboratory's existing RNA sequence analysis data (fibroblast osteoblast (hFOB 1.19) and three osteosarcoma cell lines (HOS, MG63, and U2OS) as the research object. Next, we detected Lnc-CLSTN2-1:1 in the osteosarcoma HOS cell line and fibroblast cells using qRT-PCR. We evaluated cell proliferation ability using EdU incorporation test, CCK-8 test, and cell clone formation; cell invasion and migration were assessed using the Transwell test, while flow cytometry examined cell cycle, apoptosis, and reactive oxygen species (ROS); Subsequently, the activity changes of selenase (GPx) glutathione peroxidase and (TrxR) thioredoxin reductase were detected. In addition, changes in related proteins were analyzed through Western blotting. Results: The expression of Lnc-CLSTN2-1:1 in osteosarcoma cells was significantly increased. The proliferation, invasion, and migration of osteosarcoma cells were significantly inhibited by knockdown of the expression of Lnc-CLSTN2-1:1, and the cell cycle-related signaling pathway PI3K/AKT/GSK-3β/cycinD1 was also inhibited. However, insulin-like growth factor-1 (igf-1) could reverse this process. In addition, we examined the activity of two selenophenases (TrxR and GPx) and the changes of ROS before and after Lnc-CLSTN2-1:1 knockdown. The results showed that both TrxR and GPx activities were reduced after Lnc-CLSTN2-1:1 knockdown, resulting in the inhibition of antioxidant stress levels, while intracellular ROS levels were high, which eventually caused killing effects on tumor cells due to the imbalance between oxidative stress and antioxidant stress. Conclusion: Our results showed that Lnc-CLSTN2-1:1 enhanced anti-oxidative stress TrxR and GPx selenoprotein activities through the PI3K/AKT signaling pathway while counteracting the loss of reactive oxygen species ROS produced by mitochondria to osteosarcoma cells, which protected osteosarcoma cells and thus promoted the proliferation and metastatic ability of OS.
Insights
Lnc-CLSTN2-1:1 promotes osteosarcoma progression by enhancing antioxidant defenses via the PI3K/AKT pathway. Inhibiting Lnc-CLSTN2-1:1 reduces tumor cell proliferation and metastasis, offering a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteosarcoma (OS) is an aggressive bone cancer with a poor prognosis.
- Understanding the molecular mechanisms driving OS progression is crucial for developing effective treatments.
- Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.
Purpose of the Study:
- To investigate the biological function of Lnc-CLSTN2-1:1 in osteosarcoma.
- To elucidate the underlying molecular pathways affected by Lnc-CLSTN2-1:1 in OS cells.
- To explore the potential of targeting Lnc-CLSTN2-1:1 for OS therapy.
Main Methods:
- Quantification of Lnc-CLSTN2-1:1 expression using qRT-PCR in OS and normal cells.
- Assessment of cell proliferation, invasion, migration, cell cycle, apoptosis, and reactive oxygen species (ROS) levels.
- Analysis of key protein expression via Western blotting and enzyme activity of glutathione peroxidase (GPx) and thioredoxin reductase (TrxR).
Main Results:
- Lnc-CLSTN2-1:1 expression was significantly elevated in osteosarcoma cells.
- Knockdown of Lnc-CLSTN2-1:1 inhibited OS cell proliferation, invasion, and migration, and induced apoptosis.
- Lnc-CLSTN2-1:1 promoted OS cell survival by enhancing antioxidant enzyme activities (GPx, TrxR) through the PI3K/AKT/GSK-3β/cyclinD1 pathway, while insulin-like growth factor-1 (IGF-1) reversed these effects.
Conclusions:
- Lnc-CLSTN2-1:1 promotes osteosarcoma progression by bolstering antioxidant capacity and promoting cell survival.
- The PI3K/AKT signaling pathway is a key mediator of Lnc-CLSTN2-1:1's pro-tumorigenic effects.
- Targeting Lnc-CLSTN2-1:1 may represent a novel therapeutic strategy for osteosarcoma.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
lncRNA - Long Non-coding RNAs
Abnormal Proliferation

